Divi's Laboratories
Search results
Press Release - Laurus Labs Announces Q1 FY 25 Results Revenues at ₹ 1,195 Cr; EBITDA at ₹ 171 Cr
As a research-driven pharmaceutical manufacturing organization, Laurus Labs has been developing and assisting its client organizations to succeed in innovative medicines that globally enhance the health outcomes for patients.
Contact Us. Leveraging our expertise in chemical development, Laurus Labs has crafted an extensive array of in-house Active Pharmaceutical Ingredients (APIs) and intermediates, catering to both client requirements and our own portfolio.
Laurus labs is an innovation-driven¸ people-centric & client-focused organization offering a broad and integrated portfolio of products & services to the global pharmaceutical industry.
2 days ago · Laurus Labs Share Price: Find the latest news on Laurus Labs Stock Price. Get all the information on Laurus Labs with historic price charts for NSE / BSE.
Laurus Labs is an Indian multinational pharmaceutical and biotechnology company headquartered in Hyderabad. Its focus areas include active pharmaceutical ingredients (APIs), generic formulations , custom synthesis (CDMO), biotechnology , [ 7 ] veterinary APIs and agrochemicals .
Get the latest Laurus Labs Ltd (LAURUSLABS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
5 days ago · Laurus Labs Limited Stock Price Today, Live NSE Share Price: Get the latest Laurus Labs Limited news, company updates, quotes, tips, historical charts, 52 week high low, market performance financial reports and many more at NSE India.
4 days ago · Laurus Labs Share Price Today (04 Oct, 2024): Laurus Labs Stock Price (₹ 445.15) Live NSE/BSE updates on The Economic Times. Check out why Laurus Labs share price is down today. Get all details on Laurus Labs Ltd.shares news and analysis, Forecasts, Dividend, balance sheet, profit & loss, Quarterly results, annual report information, and more
5 days ago · Laurus Labs Ltd stock dropped by over 10% from its peak in July 2024 but found support above the 200-day EMA. Experts predicted a potential rebound to 445-470 levels in 3-4 weeks. The stock exhibited bullish reversal signals, including a Bullish Harami candlestick pattern and strong 200-day moving average support.
